Reach-Through Royalty

A reach-through royalty is a licensing clause requiring the licensor of a research tool (an assay, screening platform, reagent, or similar upstream technology) to be paid a share of revenue from a future product the licensee later discovers or develops using that tool -- even though the tool's own patent claims do not cover, and are not incorporated into, that downstream product. It is distinguished from an ordinary running royalty by that gap: the royalty base is a product outside the scope of what was actually licensed.

ByCASRAI Editorial Board

· Last updated 24 Jul 2026

Ask about Reach-Through Royalty

Answers are drawn from this dictionary entry and the rest of the CASRAI corpus, with a link to every source.

Answers are AI-generated from CASRAI’s own published pages and can be wrong, so check the linked sources before relying on one; your question is logged without personal data — never sold, never used to train a third-party model — to show us what CASRAI is missing, so please do not type personal or confidential details. How we use this

Worked examples

Is an instance

A university licenses a high-throughput compound-screening platform to a biotech company and charges 1% of net sales on any product the company later identifies using the platform, even though the platform's own patent claims cover only the screening method, not any resulting compound -- a reach-through royalty because the royalty base sits entirely outside the licensed claims.

Is an instance

A research-antibody supplier licenses an antibody-generation method with no fee on the antibodies produced, but a running royalty on any therapeutic later developed using an antibody made with the method -- a reach-through license agreement (RTLA) structure discussed specifically in NIH's 1999 research-tools guidance.

Looks similar, but isn't

Not an instance

A running royalty calculated on net sales of a licensed drug is not a reach-through royalty when the licensed patent claims actually cover, or are practiced by, that drug -- the royalty base and the licensed claims match, which is ordinary product licensing, not reach-through.

Not an instance

Bayh-Dole march-in rights (35 U.S.C. 203) are a separate government-invoked remedy for inadequate practical application of a federally funded invention -- unrelated to how a licensor privately structures royalty consideration with a licensee.

A reach-through royalty is a licensing term under which a licensor of a research tool — an assay, a screening platform, a reagent, a research antibody, a cell line, a gene-editing method, a database, or similar upstream technology — claims a share of the revenue, or a royalty, on a future product the licensee later discovers, develops, or sells using that tool, even though the tool’s own patent is never incorporated into, and does not read on, the final commercial product. The related term reach-through license agreement (RTLA) refers to the license instrument built around such a clause. This is the defining problem this term addresses, and the reason it needs its own entry distinct from CASRAI’s existing License Agreement term and License Agreement Structure guide: those cover the standard clause-by-clause anatomy of a license where a running royalty is calculated on sales of a product that practices the licensed patent. A reach-through royalty is structurally different — it tries to capture value from a product the licensed patent does not cover at all.

What Makes Something an Instance of a Reach-Through Royalty

A clause is a reach-through royalty when three conditions hold together:

The licensed IP is a research tool, not a product-embodying patent. Its commercial value lies in accelerating or enabling downstream research, not in being sold, used, or embodied in an end product itself.
The royalty base is the licensee’s downstream product — a drug, diagnostic, or other commercial output discovered or developed with the tool’s help — not sales of the tool itself.
The licensed patent claims do not cover the downstream product. If the tool’s patent actually reads on the final product (for example, a licensed screening compound is incorporated directly into the marketed drug), any royalty on that product is an ordinary running royalty, not a reach-through royalty, no matter how it is labeled in the contract.

Because the tool itself often generates little or no direct commercial value on its own, the licensor’s economic logic for wanting a reach-through term is straightforward: without one, they may get only a modest up-front or per-unit fee for something that could have contributed to a blockbuster discovery downstream. The problem, from a technology transfer and public-policy perspective, is the mirror image of that logic: a reach-through obligation attaches a real cost, and often an ongoing disclosure and accounting burden, to every future product a licensee might ever develop using the tool — which can deter licensees from taking the tool at all, or push them toward a functionally equivalent but unencumbered alternative, undermining the exact goal (widespread research use) the tool was created to serve.

Why This Comes Up in University and NIH-Funded Licensing Specifically

The concern is not abstract for federally funded research. NIH’s Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources (Federal Register, final notice, December 23, 1999; also issued as NIH Guide Notice NOT-OD-00-013) directs recipients of NIH funding to avoid imposing reach-through royalty or reach-through licensing obligations as a condition of providing research tools to other investigators. The guidance frames unrestricted or lightly restricted access to research tools as central to the pace of biomedical progress, and treats reach-through terms as a structural drag on that access — a downstream licensee facing an open-ended future royalty obligation on products not yet conceived has a strong incentive to avoid the tool altogether. This sits alongside, and reinforces, the broader obligations research institutions already take on under the Bayh-Dole Act (35 U.S.C. §§ 200-212) when they elect to retain title to a federally funded invention: the Act’s underlying policy goal is to promote utilization and commercialization of federally funded inventions, and a licensing practice that chills third-party use of a foundational research tool cuts against that same goal, even where Bayh-Dole itself does not directly prohibit the specific clause.

In practice, most university technology transfer offices (TTOs) now treat reach-through royalties on research tools as disfavored for exactly this reason, particularly where the tool is a genuine platform technology (an assay format, a model organism, a broadly useful reagent) rather than a narrow, product-specific asset. That does not mean reach-through-shaped terms have disappeared entirely — see the alternatives below — but a licensor proposing one on a federally funded research tool should expect a licensee, especially a well-advised one, to push back citing this exact guidance.

Worked Examples

Reach-through royalty. A university licenses a high-throughput compound-screening platform to a biotech company for internal drug discovery use. The license requires the company to pay the university 1% of net sales on any product that the company identifies using the platform during the license term, for the life of that product’s own patent — even though the platform’s patent claims cover only the screening method itself, not any compound the method might help discover. This is a reach-through royalty: the royalty base is a future, as-yet-unidentified product outside the scope of the licensed claims.
Reach-through license agreement structure. A research-antibody supplier licenses a proprietary antibody-generation method to a pharmaceutical company, with no upfront fee and no per-unit fee on the antibodies themselves, but a running royalty on any therapeutic that reaches the market having been developed with an antibody generated via the method. The absence of any royalty tied to the tool’s own use, paired entirely with a royalty on downstream products, is the RTLA pattern the NIH guidance specifically discusses.

Counter-Examples — What This Is Not

An ordinary running royalty on a licensed product patent is not a reach-through royalty, even if the royalty rate is calculated on the licensee’s net sales of a downstream drug or device — because in that case the licensed patent claims actually cover, or are practiced by, that product. See CASRAI’s License Agreement Structure guide for how a standard “Net Sales” / running-royalty clause is built. The distinguishing question is always whether the licensed claims read on the thing being royalty-bearing, not whether the royalty is described as running on future sales.
Milestone or equity consideration for a research tool — a one-time payment triggered by the licensee reaching a development milestone, or an equity stake taken in lieu of cash — is a different risk-sharing mechanism, not a reach-through royalty, unless it is specifically pegged to royalties on a downstream product outside the licensed claims.
March-in rights under Bayh-Dole are a separate, government-invoked remedy for inadequate practical application of a federally funded invention — unrelated to how a licensor structures royalty consideration with a private licensee.

Alternatives Licensors and TTOs Use Instead

Because a bare reach-through royalty on a broadly useful research tool tends to chill adoption, technology transfer practice has converged on several substitutes that let a licensor still participate in downstream success without imposing an open-ended obligation on every future product:

Higher up-front and annual maintenance fees, sized to reflect the tool’s expected research value, in place of a royalty tied to unknown future products.
Non-exclusive licensing at modest, flat per-use or per-unit fees, maximizing the number of research groups with access rather than trying to capture a share of any one group’s eventual commercial success.
Reservation of rights to a specific downstream product actually identified through use of the tool, narrowly scoped and time-limited, rather than an open-ended claim on any and all future products.
Sponsored-research or option agreements that give the tool provider a time-limited right to negotiate a separate license if and when a specific downstream candidate emerges, rather than a standing royalty obligation baked into the original tool license.

Each of these keeps the tool provider’s economic interest in downstream success intact while avoiding the specific structural problem the NIH guidance flags: an obligation whose scope and value cannot be known at the time the tool is licensed, attached to every future product a licensee might ever develop.

Use in your systems

JATS XML <role> element

xml

<role vocab="credit"
      vocab-identifier="https://casrai.org/dictionary/"
      vocab-term="Reach-Through Royalty"
      vocab-term-identifier="https://casrai.org/dictionary/term/reach-through-royalty" />

Schema.org DefinedTerm (JSON-LD)

json

{
  "@context": "https://schema.org",
  "@type": "DefinedTerm",
  "@id": "https://casrai.org/dictionary/term/reach-through-royalty",
  "name": "Reach-Through Royalty",
  "identifier": "https://casrai.org/dictionary/term/reach-through-royalty",
  "description": "A reach-through royalty is a licensing clause requiring the licensor of a research tool (an assay, screening platform, reagent, or similar upstream technology) to be paid a share of revenue from a future product the licensee later discovers or develops using that tool -- even though the tool's own patent claims do not cover, and are not incorporated into, that downstream product. It is distinguished from an ordinary running royalty by that gap: the royalty base is a product outside the scope of what was actually licensed.",
  "inDefinedTermSet": "https://casrai.org/dictionary/domain/tech-transfer#set",
  "url": "https://casrai.org/dictionary/term/reach-through-royalty",
  "sameAs": [
    "reach-through license agreement",
    "RTLA",
    "reach-through licensing"
  ],
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "publisher": {
    "@id": "https://casrai.org/#organization"
  },
  "dateModified": "2026-07-24T06:33:53",
  "inLanguage": "en"
}